Moderna (MRNA) closed at $34.01 in the latest trading session, marking a -1.9% move from the prior day. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the ...

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

The most recent trading session ended with Moderna (MRNA) standing at $24.73, reflecting a -1.85% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's ...

Why Moderna stock fell. Moderna's bizarre stock price performance during the week ending May 31 had two main factors. First, enthusiasm for the vaccine developer's artificial intelligence ...

Overall, the performance of MRNA stock with respect to the index has been quite volatile. Returns for the stock were 143% in 2021, -29% in 2022, and -45% in 2023.

Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...

These ratings communicate expectations for the relative performance of Moderna compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value.

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock dropped even further after lowering its expected revenue range for 2025 ...

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks to several potential product launches. A lot can happen in 10 years ...